Neoplasms

Blood and Lymph Conditions

All Conditions

Rare Diseases

Leukemia

Neoplasms by Histologic Type

Hematologic Diseases

Acute Graft Versus Host Disease

Administration of 20 fraction of the UCBT

DLI of the 20 fraction of the UCBT

Sergio Querol, PhD

Pilot, multicentric, open-label, single-arm, phase I-II clinical trial to evaluate the safety and efficacy of a novel Umbilical Cord Blood Transplantation (UCBT) platform, that consists of a UCBT of the 80 fraction, followed by a Donor Lymphocyte Infusion (DLI) of the 20 fraction (between 60 and 90 days after transplantation).

Multicenter, open-label, single-arm, phase I-II pilot study in which a minimum of 20 patients will enter the study with the primary objective to assess the safety and secondary objective to assess efficacy in relation to immune reconstitution followed by a new platform of treatment consisting of initial cord blood unit 80 fraction transplantation, followed by a prophylactic donor lymphocyte infusion (DLI) of the fraction 20 of the cord blood unit. The second infusion will take place between 60 and 90 days after transplantation.

Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation

Subpopulations of Lymphocytes T: CD4 and CD8

Hospital Vall d'Hebron

Hospital de Sant Pau

Hospital Universitari de Bellvitge

Germans Trias i Pujol Hospital

Fundacion IMIM

Banc de Sang i Teixits

Spots Global Cancer Trial Database for dli of the 20 fraction of the ucbt